Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Date:2/21/2013

THE WOODLANDS, Texas, Feb. 21, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2012.

"We continued to make significant progress in the development of our pipeline in 2012, highlighted by positive results from clinical studies of LX4211 in diabetes and telotristat etiprate in carcinoid syndrome," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "We are pleased to have commenced the Phase 3 program for telotristat etiprate in carcinoid syndrome, and continue to progress in our preparations for LX4211 Phase 3 initiation. We also look forward to significant proof-of-concept results in irritable bowel syndrome (IBS) with LX1033, ulcerative colitis with telotristat etiprate, and type 1 diabetes with LX4211 in 2013."

Key Developments in 2012

  • LX4211:  Lexicon reported positive results from a 12-week Phase 2b clinical trial of LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2) in patients with type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy. LX4211 treatment produced substantial, dose-dependent and statistically-significant reductions in hemoglobin A1c (HbA1c), with patients in the high dose (400 mg QD) LX4211 treatment arm having a mean HbA1C reduction from baseline of 0.95 percent (p<0.001). In patients randomized to placebo, HbA1C decreased by 0.09 percent. LX4211 treatment also produced significant reductions in body weight and blood pressure. In addition, Lexicon initiated a study in type 2 diabetes patients with renal impairment.
  • Telotristat etiprate (LX1032):  Lexicon initiated a pivotal Phase 3 clinical trial of telotristat etiprate, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels. The Phase 3 registrational trial is a 12-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of telotristat etiprate as a new treatment for carcinoid syndrome that is refractory to current therapy.  The study is expected to enroll approximately 105 patients.  Lexicon reported data from an open-label Phase 2 trial in which telotristat etiprate showed evidence of clinical benefit across several endpoints in carcinoid syndrome patients. Benefits included reductions in bowel movement frequency, decreased urinary 5-HIAA (a biomarker of serotonin synthesis), and improvements in patient-reported relief of symptoms. Lexicon received Orphan Drug designation for telotristat etiprate from the U.S. Food and Drug Administration (FDA) for the treatment of carcinoid syndrome, having previously obtained Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA). In addition to ongoing development in carcinoid syndrome, Lexicon also initiated a Phase 2 proof-of-concept study of telotristat etiprate in patients with ulcerative colitis.
  • LX1033: Lexicon initiated a Phase 2 clinical trial of LX1033, an inhibitor of tryptophan hydroxylase that acts locally in the gastrointestinal tract to reduce serotonin production, in patients with diarrhea-predominant IBS (IBS-d). The Phase 2 trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of LX1033 in approximately 360 IBS-d patients. Lexicon also received Fast Track status from the FDA for the development of LX1033 in IBS-d.
  • Other Programs: Lexicon obtained results from Phase 1 studies of  LX2931, an inhibitor of sphingosine-1-phosphate lyase, in patients with rheumatoid arthritis, and LX7101, an inhibitor of LIM domain kinase 2 (LIMK2), in patients with glaucoma.  Both compounds were well-tolerated and showed signals of clinical benefit in the respective studies.
  • Financial ResultsRevenues:  Lexicon's revenues for the three months ended December 31, 2012 decreased 36 percent to $0.2 million from $0.3 million for the corresponding period in 2011. For the year ended December 31, 2012, revenues decreased 41 percent to $1.1 million from $1.8 million for the corresponding period in 2011.

    Research and Development Expenses:  Research and development expenses for the three months ended December 31, 2012 decreased 25 percent to $21.0 million from $28.1 million for the corresponding period in 2011, primarily due to a decrease in external manufacturing, clinical research and development costs. For the year ended December 31, 2012, research and development expenses decreased 10 percent to $82.6 million from $91.8 million for the corresponding period in 2011.

    Increase (Decrease) in Fair Value of Symphony Icon Purchase Liability:  In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated base and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations. For the three months ended December 31, 2012, the fair value of the Symphony Icon purchase liability decreased by $0.2 million, compared to an increase of $1.6 million in the corresponding period in 2011. For the years ended December 31, 2012 and 2011, the increase in fair value of the Symphony Icon purchase liability was $9.9 million and $6.8 million, respectively.

    General and Administrative Expenses:  General and administrative expenses for the three months ended December 31, 2012 decreased two percent to $3.9 million from $4.0 million for the corresponding period in 2011. For the year ended December 31, 2012, general and administrative expenses decreased two percent to $17.0 million from $17.4 million for the corresponding period in 2011.

    Consolidated Net Loss:  Net loss for the three months ended December 31, 2012 was $24.9 million, or $0.05 per share, compared to a net loss of $33.8 million, or $0.10 per share, in the corresponding period in 2011. Net loss for the year ended December 31, 2012 was $110.2 million, or $0.23 per share, compared to a net loss of $116.2 million, or $0.34 per share, for the corresponding period in 2011. For the three months and year ended December 31, 2012, net loss included non-cash, stock-based compensation expense of $1.6 million and $6.5 million, respectively. For the three months and year ended December 31, 2011, net loss included non-cash, stock-based compensation expense of $1.4 million and $5.7 million, respectively.

    Cash and Investments:  As of December 31, 2012, Lexicon had $223.2 million in cash and investments, as compared to cash and investments of $206.8 million as of September 30, 2012 and $281.7 million as of December 31, 2011.

    Lexicon Conference Call
    Lexicon management will hold a conference call to discuss its clinical development progress and financial results for 2012 and financial guidance for 2013 at 11:00 a.m. Eastern Time on February 21, 2013. The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international). The conference ID for all callers is 12316846. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through March 21, 2013.

    About Lexicon
    Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple drug programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

    Safe Harbor Statement

    This press release contains "forward-looking statements", including statements relating to Lexicon's clinical development of LX4211, telotristat etiprate (LX1032), LX1033, LX2931 and LX7101, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211, telotristat etiprate (LX1032), LX1033, LX2931 and LX7101.  In addition, this press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211, telotristat etiprate (LX1032), LX1033, LX2931 and LX7101 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc.
    Selected Financial Data

     Consolidated Statements of Operations DataThree Months EndedDecember 31,Year EndedDecember 31,(In thousands, except per share data)2012201120122011(unaudited)  (unaudited)Revenues:Collaborative research

    $
    218$
    320$
    783$
    ,632Subscription and license fees

    -23306217Total revenues

    2183431,0891,849Operating expenses:Research and development, including stock-based compensation

    of $798, $769, $3,673 and $3,249, respectively

    20,99028,10782,57491,828Increase (decrease) in fair value of Symphony Icon, Inc
    purchase liability

    (200)1,5689,8876,766General and administrative, including stock-based compensation

    of $792, $584, $2,822 and $2,458, respectively

    3,9204,01017,04317,350Total operating expenses

    24,71033,685109,504115,944Loss from operations

    (24,492)(33,342)(108,415)(114,095)Interest income

    5540213255Interest expense

    (520)(551)(2,114)(2,528)Other income, net

    848105153Consolidated net loss

    $  (24,873)$  (33,845)$ (110,211)$ (116,215)Consolidated net loss per common share, basic and diluted

    $
    (0.05)$
    (0.10)$
    (0.23)$
    (0.34)Shares used in computing consolidated net loss per common share, basic and diluted507,619350,069489,707340,761Consolidated Balance Sheet DataAs of December 31,As of December 31,(In thousands)20122011(unaudited)Cash and investments

    $
    223,208$
    281,692Property and equipment, net

    42,63446,417Goodwill44,54344,543Other intangible assets

    53,55753,557Total assets

    371,778430,512Deferred revenue

    14,03814,331Current and long-term debt

    23,45124,894Other long-term liabilities

    32,28355,146Accumulated deficit

    (899,832)(789,621)Total stockholders' equity

    266,678297,568


    '/>"/>
    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Lexicon To Present At The BIO CEO & Investor Conference
    2. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
    3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
    4. Lexicon to Provide Third Quarter 2012 Financial Results
    5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
    6. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
    7. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
    8. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
    9. Lexicon to Provide Second Quarter 2012 Financial Results
    10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
    11. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/12/2016)... Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... the Company will ring the Nasdaq Closing Bell at ... York at 4:00 p.m. ET on Tuesday, ... Adrian Adams , will perform the ... to 4:00 p.m. ET.  A live webcast will be ...
    (Date:2/12/2016)... February 12, 2016 ... auf den ungedeckten medizinischen Bedarf bei Lungen- ... seines klinischen Forschungsprogramms bekannt. Das Programm, das ... Verbesserungen ihrer respiratorischen Funktionen und anderer klinischer ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ...
    (Date:2/11/2016)... Stem cells are primitive cells found in all multi-cellular ... to differentiate into mature cell types Stem cells are ... embryonic stem cells were derived from embryos in 1981, ... culturing of embryonic stem cells from non-human primates occurred ... As a result of these discoveries, stem cells can ...
    Breaking Medicine Technology:
    (Date:2/12/2016)... ... February 12, 2016 , ... For Coast Dental dentist Everet Lake, DDS, ... dental assistant Terrell Moore shortly before 7 a.m. to volunteer at Friday’s Dentistry from ... their time and skills to help hundreds of uninsured and underinsured people receive much-needed ...
    (Date:2/12/2016)... , ... February 12, 2016 , ... ... a world of exterior design possibilities. CertainTeed, North America’s leading brand of building ... expanding the product offerings showcased in the mobile version of the ColorView® Exterior ...
    (Date:2/12/2016)... ... February 12, 2016 , ... The aging ... field of long term care. With that, says Patrick Loughney, president of ... administrative roles in long term care environments. His company, which offers prep courses ...
    (Date:2/12/2016)... ... ... Dignity Health named Dr. Scott Bingham the Facility Medical Director of the new ... under Dignity Health Arizona General Hospital , which opened last year in the ... new freestanding emergency room delivers the highest quality care to Mesa and the surrounding ...
    (Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... participated in the American Osteopathic Association’s (AOA) Match Program Tuesday, February 9, taking ... Program places students into osteopathic graduate medical education positions across the country. Of ...
    Breaking Medicine News(10 mins):